Yeji
NDA/BLA filedconf 0.95

axs-12 — NDA/BLA filed

$AXSM · Axsome Therapeutics, Inc. · cataplexy in narcolepsy
Event date
July 15, 2026
12 days ago
Sponsor runway
44 mo
$305.1M liquid

Evidence

the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy
Source: 8-K filed 2026-07-15View on EDGAR ↗0001193125-26-304039

Comparable historical nda/bla fileds· last 5 years · same event type

TickerDrugDateOutcome
$AXSM2025-12-31unknown
$RCKTkresladi2025-10-14unknown
$ALDXreproxalap2025-07-17unknown
$ETONet-6002025-07-08unknown
$BCRXorladeyo (berotralstat)2025-05-14unknown
$CORTrelacorilant2025-03-03unknown
$ALDXreproxalap2024-11-01unknown
$AXSMaxs-072024-09-04unknown
$RCKTkresladi2023-10-02unknown
$GERNimetelstat2023-08-21unknown

Recent insider activity· ±90 days

5 insiders · 0 buys · 3 sells
Exercise10b5-1
2026-05-05
Jacobson Mark L.
Chief Operating Officer
233 @ $12.95$3K
Sell10b5-1
2026-05-05
Jacobson Mark L.
Chief Operating Officer
233 @ $228.18$53K
Sell10b5-1
2026-05-04
Jacobson Mark L.
Chief Operating Officer
4,517 @ $227.94$1.03M
Exercise10b5-1
2026-05-04
Jacobson Mark L.
Chief Operating Officer
4,517 @ $12.95$58K
Exercise10b5-1
2026-04-22
Maizel Ari
Chief Commercial Officer
7,500 @ $70.73$530K
Sell10b5-1
2026-04-22
Maizel Ari
Chief Commercial Officer
7,500 @ $182.42$1.37M
Grant
2026-04-21
TABUTEAU HERRIOT
Chief Executive Officer
24,081 @
Grant
2026-04-21
Maizel Ari
Chief Commercial Officer
7,224 @
Grant
2026-04-21
Jacobson Mark L.
Chief Operating Officer
8,669 @
Grant
2026-04-21
Murdock Hunter R.
General Counsel
7,224 @
Grant
2026-04-21
Pizzie Nick
Chief Financial Officer
8,188 @